Adolor (ADLR) Continues to Soar!

FOR IMMEDIATE RELEASE
West Bloomfield, Michigan, United States of America (Free-Press-Release.com) July 8, 2011 --

Adolor Corporation's (ADLR) breakout move this week added another 25% to it's stock price. Buyers have been forced to chase this stock up because of the small amount of float available. Joseph Capaldi II, Chief Financial Analyst at Professional Trading stated the move is typical with stocks with a small amounts of outstanding shares. Capaldi first recommended ADLR at $1.11. We saw the base building along with their strong pipeline of drugs. This is not your ordinary drug company, Capaldi says. This company is working on one of a kind drugs and is already making money with their in-hospital pain treatment, ENTEREG®, . Adolor hopes to get approval for out of hospital use with ENTEREG®, which will increase revenues.

Michael J. Fox Foundation for Parkinson's Research awarded Adolor two rounds of funding to support their development of CAMORs for the treatment of LID associated with Parkinson's disease.

Adolor Corporation (ADLR) is a bio-pharmaceutical company focused on the development and commercialization of novel prescription pain and pain-management products. Adolor's mission addresses a simple goal: to provide enhanced relief for the millions of people who suffer from pain each year.

Adolor reach a high of $2.64 today and is still considered a strong buy with tremendous upside.

Bio Technology     ENTEREG     Michael J. Fox Foundation     ProTSC     Stocks Breakout     stocks new high     strong buy     Undervalued Stock